Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372657 | 0.87 | TAAR1 (0.47) | TAAR1HTR2ACYP3A4HTR2CGAA | |
| SCHEMBL1886751 | 0.82 | HTR2A (0.52) | TAAR1HTR2ACYP3A4GAAMAPT | |
| SCHEMBL27855139 | 0.79 | HTR2A (0.41) | TAAR1HTR2ACYP3A4HTR2CTSHR | |
| SCHEMBL10717601 | 0.79 | CYP3A4 (0.41) | CYP3A4MAPTTSHR | |
| SCHEMBL4042555 | 0.77 | CYP3A4 (0.45) | TAAR1HTR2ACYP3A4MAPT | |
| SCHEMBL29643005 | 0.77 | CYP3A4 (0.45) | TAAR1HTR2ACYP3A4MAPT | |
| SCHEMBL10730344 | 0.77 | TAAR1 (0.60) | TAAR1HTR2ACYP3A4GAAMAPT | |
| SCHEMBL5181298 | 0.74 | CYP3A4 (0.43) | HTR2ACYP3A4GAAMAPTTSHR | |
| SCHEMBL1942790 | 0.72 | HTR2A (0.42) | TAAR1HTR2AHTR2CGAAMAPT | |
| SCHEMBL11696028 | 0.72 | HTR2A (0.37) | TAAR1HTR2ACYP3A4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7060851-B2 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. | 2003-09-11 | — | — | US | disclosed |
| US-6515162-B2 | Precipitating or crystallizing a salt from solution; suitable as intermediates for large scale production of enzyme inhibitors, e.g. hydroxyethylamine, hydroxyethylurea and hydroxyethylsulfonamide | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | NG JOHN S (US) | 2001-11-29 | — | — | US | disclosed |
| EP-0804410-B1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | SEARLE & CO (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6201150-B1 | DIASTEREOMER PURIFICATION METHOD COMPRISING PREPARING AN ORGANIC ACID OR INORGANIC ACID SALT OF AN AMINO COMPOUND AND PRECIPITATING OR CRYSTALLIZING SAID SALT FROM A SOLUTION | G.D. SEARLE & CO. | 2001-03-13 | — | — | US | disclosed |
| US-5831117-A | ACID SALTS | G. D. SEARLE & CO. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | ACE, REN, MME | TAAR1 3637/4885HTR2A 3212/4885CYP3A4 1201/4885 |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | TAAR1 3526/4885HTR2A 2839/4885CYP3A4 954/4885 |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | TAAR1 3526/4885HTR2A 2839/4885CYP3A4 954/4885 |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | TAAR1 3644/4885HTR2A 2800/4885CYP3A4 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.